title: Gene expression profiling in vLINCL CLN6-deficient fibroblasts: Insights into pathobiology.
abstract: The CLN6 vLINCL is caused by molecular defects in CLN6 gene coding for an ER resident transmembrane protein whose function is unknown. In the present study gene expression profiling of CLN6-deficient fibroblasts using cDNA microarray was undertaken in order to provide novel insights into the molecular mechanisms underlying this neurodegenerative fatal disease. Data were validated by qRT-PCR. Statistically significant alterations of expression were observed for 12 transcripts. The two most overexpressed genes, versican and tissue factor pathway inhibitor 2, are related to extracellular matrix (ECM), predicting changes in ECM-related proteins in CLN6-deficient cells. Transcript profiling also suggested alterations in signal transduction pathways, apoptosis and the immune/inflammatory response. Up-regulated genes related to steroidogenesis or signalling, and the relationship between cholesterol dynamics and glycosphingolipid sorting, led to investigation of free cholesterol and gangliosides in CLN6-deficient fibroblasts. Cholesterol accumulation in lysosomes suggests a homeostasis block as a result of CLN6p deficiency. The cholesterol imbalance may affect structure/function of caveolae and lipid rafts, disrupting signalling transduction pathways and sorting cell mechanisms. Alterations in protein/lipid intracellular trafficking would affect the composition and function of endocytic compartments, including lysosomes. Dysfunctional endosomal/lysosomal vesicles may act as one of the triggers for apoptosis and cell death, and for a secondary protective inflammatory response. In conclusion, the data reported provide novel clues into molecular pathophysiological mechanisms of CLN6-deficiency, and may also help in developing disease biomarkers and therapies for this and other neurodegenerative diseases.
authors.affiliation: Unidade de Enzimologia, Instituto de Genética Médica Jacinto Magalhães, Porto, Portugal.
authors.forename: C A F
authors.initials: CA
authors.lastname: Teixeira
authors.forename: S
authors.initials: S
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Mangas
authors.forename: R
authors.initials: R
authors.lastname: Quinta
authors.forename: C J P
authors.initials: CJ
authors.lastname: Bessa
authors.forename: C
authors.initials: C
authors.lastname: Ferreira
authors.forename: M C
authors.initials: MC
authors.lastname: Sá Miranda
authors.forename: R-M N
authors.initials: RM
authors.lastname: Boustany
authors.forename: M G
authors.initials: MG
authors.lastname: Ribeiro
mesh_terms: D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D011508:Chondroitin Sulfate Proteoglycans / Q000235:genetics; D017931:DNA Primers; D005347:Fibroblasts / Q000502:physiology; D020869:Gene Expression Profiling; D006801:Humans; D037181:Lectins, C-Type / Q000235:genetics; D008565:Membrane Proteins / Q000235:genetics*; D009472:Neuronal Ceroid-Lipofuscinoses / Q000235:genetics* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012879:Skin Physiological Phenomena; D053675:Versicans
chemical_list: C447500:CLN6 protein, human; D011508:Chondroitin Sulfate Proteoglycans; D017931:DNA Primers; D037181:Lectins, C-Type; D008565:Membrane Proteins; C508322:VCAN protein, human; D053675:Versicans; D002784:Cholesterol